Baidu
map

Nat Commun:新药CCT365623:切断癌症扩散的后路

2017-04-19 Heather_z727 来宝网

伦敦癌症研究中心的科学家和曼彻斯特大学的研究人员找到了抗击乳腺癌的新方法。科学家们发现一个促使乳腺癌发展和转移的新机制,并设计了阻隔其作用的新药。



伦敦癌症研究中心的科学家和曼彻斯特大学的研究人员找到了抗击乳腺癌的新方法。科学家们发现一个促使乳腺癌发展和转移的新机制,并设计了阻隔其作用的新药。

研究人员确定一种叫做赖氨酰化氧的蛋白质,或液态氧是乳腺癌肿瘤形成,发展和转移的幕后推手。在通过对小鼠的试验中,研究人员发现液体氮似乎可以帮助肿瘤“围困”表面的生长神经末梢,成为更加快速发展的途径。

在此次试验中,研究人员设计了名为CCT365623的新药,可以阻隔这一功能,并有效减缓肿瘤的生长和转移。完整的研究报告发表于今天的《自然通讯》杂志中。

先前,大家对液态氮的认识是控制细胞外基质形成,现如今科学家发现它可以被癌细胞利用,用来更快的发展和转移。此次研究是第一次把液态氮和肿瘤生长联系起来,因此,研究人员设计了名为CCT365623的抑制剂,在对小鼠的试验证明,这种抑制剂可以有效减缓肿瘤的生长速度,而且没有表现出明显的副作用。

研究人员表示:“此次试验的结果是令人欣喜的,因为我们不但找到了肿瘤转移的新细节,而且我们还找到了抑制其发展的方法。我们都知道,癌症一旦转移是非常难治疗的,希望我们的研究可以提高乳腺癌的治疗效果,并且也能运用于其他类型的癌症。”

原始出处:
HaoRan Tang, Leo Leung, Grazia Saturno, et al. Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface, Nature Communications (2017). DOI: 10.1038/ncomms14909

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1881923, encodeId=52a1188192372, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 22 16:56:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968086, encodeId=4ca81968086cc, content=<a href='/topic/show?id=6d20424203' target=_blank style='color:#2F92EE;'>#CCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4242, encryptionId=6d20424203, topicName=CCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Mon Jan 22 09:56:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936839, encodeId=709a1936839a4, content=<a href='/topic/show?id=e6624243fe' target=_blank style='color:#2F92EE;'>#CCT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4243, encryptionId=e6624243fe, topicName=CCT3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sun May 28 00:56:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086994, encodeId=d8ec2086994ab, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jun 23 19:56:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948322, encodeId=cecb194832201, content=<a href='/topic/show?id=387ae13627c' target=_blank style='color:#2F92EE;'>#癌症扩散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71362, encryptionId=387ae13627c, topicName=癌症扩散)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Tue Jan 30 06:56:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189635, encodeId=caff1896357c, content=期待后续研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Sat Apr 22 14:46:31 CST 2017, time=2017-04-22, status=1, ipAttribution=)]
    2017-12-22 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1881923, encodeId=52a1188192372, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 22 16:56:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968086, encodeId=4ca81968086cc, content=<a href='/topic/show?id=6d20424203' target=_blank style='color:#2F92EE;'>#CCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4242, encryptionId=6d20424203, topicName=CCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Mon Jan 22 09:56:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936839, encodeId=709a1936839a4, content=<a href='/topic/show?id=e6624243fe' target=_blank style='color:#2F92EE;'>#CCT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4243, encryptionId=e6624243fe, topicName=CCT3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sun May 28 00:56:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086994, encodeId=d8ec2086994ab, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jun 23 19:56:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948322, encodeId=cecb194832201, content=<a href='/topic/show?id=387ae13627c' target=_blank style='color:#2F92EE;'>#癌症扩散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71362, encryptionId=387ae13627c, topicName=癌症扩散)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Tue Jan 30 06:56:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189635, encodeId=caff1896357c, content=期待后续研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Sat Apr 22 14:46:31 CST 2017, time=2017-04-22, status=1, ipAttribution=)]
    2018-01-22 wshxjq
  3. [GetPortalCommentsPageByObjectIdResponse(id=1881923, encodeId=52a1188192372, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 22 16:56:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968086, encodeId=4ca81968086cc, content=<a href='/topic/show?id=6d20424203' target=_blank style='color:#2F92EE;'>#CCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4242, encryptionId=6d20424203, topicName=CCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Mon Jan 22 09:56:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936839, encodeId=709a1936839a4, content=<a href='/topic/show?id=e6624243fe' target=_blank style='color:#2F92EE;'>#CCT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4243, encryptionId=e6624243fe, topicName=CCT3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sun May 28 00:56:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086994, encodeId=d8ec2086994ab, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jun 23 19:56:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948322, encodeId=cecb194832201, content=<a href='/topic/show?id=387ae13627c' target=_blank style='color:#2F92EE;'>#癌症扩散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71362, encryptionId=387ae13627c, topicName=癌症扩散)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Tue Jan 30 06:56:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189635, encodeId=caff1896357c, content=期待后续研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Sat Apr 22 14:46:31 CST 2017, time=2017-04-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1881923, encodeId=52a1188192372, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 22 16:56:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968086, encodeId=4ca81968086cc, content=<a href='/topic/show?id=6d20424203' target=_blank style='color:#2F92EE;'>#CCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4242, encryptionId=6d20424203, topicName=CCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Mon Jan 22 09:56:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936839, encodeId=709a1936839a4, content=<a href='/topic/show?id=e6624243fe' target=_blank style='color:#2F92EE;'>#CCT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4243, encryptionId=e6624243fe, topicName=CCT3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sun May 28 00:56:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086994, encodeId=d8ec2086994ab, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jun 23 19:56:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948322, encodeId=cecb194832201, content=<a href='/topic/show?id=387ae13627c' target=_blank style='color:#2F92EE;'>#癌症扩散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71362, encryptionId=387ae13627c, topicName=癌症扩散)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Tue Jan 30 06:56:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189635, encodeId=caff1896357c, content=期待后续研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Sat Apr 22 14:46:31 CST 2017, time=2017-04-22, status=1, ipAttribution=)]
    2017-06-23 liuli5079
  5. [GetPortalCommentsPageByObjectIdResponse(id=1881923, encodeId=52a1188192372, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 22 16:56:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968086, encodeId=4ca81968086cc, content=<a href='/topic/show?id=6d20424203' target=_blank style='color:#2F92EE;'>#CCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4242, encryptionId=6d20424203, topicName=CCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Mon Jan 22 09:56:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936839, encodeId=709a1936839a4, content=<a href='/topic/show?id=e6624243fe' target=_blank style='color:#2F92EE;'>#CCT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4243, encryptionId=e6624243fe, topicName=CCT3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sun May 28 00:56:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086994, encodeId=d8ec2086994ab, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jun 23 19:56:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948322, encodeId=cecb194832201, content=<a href='/topic/show?id=387ae13627c' target=_blank style='color:#2F92EE;'>#癌症扩散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71362, encryptionId=387ae13627c, topicName=癌症扩散)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Tue Jan 30 06:56:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189635, encodeId=caff1896357c, content=期待后续研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Sat Apr 22 14:46:31 CST 2017, time=2017-04-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1881923, encodeId=52a1188192372, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Dec 22 16:56:00 CST 2017, time=2017-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968086, encodeId=4ca81968086cc, content=<a href='/topic/show?id=6d20424203' target=_blank style='color:#2F92EE;'>#CCT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4242, encryptionId=6d20424203, topicName=CCT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fd34186, createdName=wshxjq, createdTime=Mon Jan 22 09:56:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936839, encodeId=709a1936839a4, content=<a href='/topic/show?id=e6624243fe' target=_blank style='color:#2F92EE;'>#CCT3#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4243, encryptionId=e6624243fe, topicName=CCT3)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=82ba2500166, createdName=ms1467340776200723, createdTime=Sun May 28 00:56:00 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2086994, encodeId=d8ec2086994ab, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Fri Jun 23 19:56:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1948322, encodeId=cecb194832201, content=<a href='/topic/show?id=387ae13627c' target=_blank style='color:#2F92EE;'>#癌症扩散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71362, encryptionId=387ae13627c, topicName=癌症扩散)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/vLodSSFTQLpHtfwJicWJibSWH7pbiauxvpCMvQIv0N9Oes8vHkDkCIW2HNDkt7icUq3RCZiaDcHR9Rap17fFySRbiaFg/132, createdBy=9f202500205, createdName=ms3297076796458174, createdTime=Tue Jan 30 06:56:00 CST 2018, time=2018-01-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=189635, encodeId=caff1896357c, content=期待后续研究!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Sat Apr 22 14:46:31 CST 2017, time=2017-04-22, status=1, ipAttribution=)]
    2017-04-22 Jianghuiqin

    期待后续研究!

    0

Baidu
map
Baidu
map
Baidu
map